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A B S T R A C T
Screening for colorectal cancer (CRC) has become established to varying degrees in several
Western countries for the past 30 years. Because of its effectiveness, screening has been
adopted or is planned in a number of other countries. In most countries, the screening
method (e.g., fecal occult blood test [FOBT], sigmoidoscopy) is followed by colonoscopy, for
verification. In other countries (e.g., United States, Germany), colonoscopy is the preferred
first-line investigationmethod. However, because colonoscopy is considered to be invasive,
might be poorly tolerated, and can be associated with complications, the idea of adopting
colonoscopy as the primary screening method suffers. Negative effects of screening meth-
ods can reduce participation in programs and thereby negate the desired effect on individ-
ual and societal health. At present, there is no generally accepted method either to assess
the perception and satisfaction of patients screened or the outcome of the screening pro-
cedures in CRC. In this review, we discuss the past development and present availability of
instruments to measure health-related quality of life (HRQoL), the scarce studies in which
such instruments have been used in screening campaigns, and the findings.We suggest the
creation of a specific instrument for the assessment of HRQoL in CRC screening.
Copyright © 2011, International Society for Pharmacoeconomics and Outcomes Research(ISPOR). Published by Elsevier Inc.
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ncidence of colorectal cancer (CRC) has increased sharply in
he Western world since 1970 [1]. In the United States, CRC is
he third most common cancer in terms of incidence and the
hird leading cause of cancer death after lung cancer, prostate
ancer in men, and breast cancer in women [2,3]. In Europe,
RC is the second most frequent cancer and the third leading
ause of cancer death after lung and breast cancers in men
nd women [3]. A steady increase of environmental risk fac-
* Address correspondence to: Elena Pizzo, Imperial College London
E-mail: e.pizzo@imperial.ac.uk.
098-3015/$36.00 – see front matter Copyright © 2011, Internation
ublished by Elsevier Inc.oi:10.1016/j.jval.2010.10.018ors for CRC (obesity, smoking, low physical activity, poor diet)
as created the need for CRC prevention not only in Western
ountries but recently also in Asia [4]. This need has resulted
n an appeal from the European Commission to its member
tates to establish CRC screening programs nationwide. At
resent, this recommendation has been followed to varying
egrees—with a certain eagerness of some Eastern European
ountries in which the level of CRC incidence was particularly
igh [5], and with hesitation and slowness in some Western
uropean countries with a similar incidence [1].
siness School, South Kensington Campus, London SW7 2AZ, UK.
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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153V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 5 2 – 1 5 9Fecal occult blood test (FOBT) traditionally has been the
ost common test used in CRC screening, but in later years
igmoidoscopy and colonoscopy have become increasingly
opular choices. In the United States and Germany, colonos-
opy is strongly promoted as the first-line screening method,
hereas prescreening with FOBT is recommended in other
ountries, such as the United Kingdom. An overview of the
haracteristics of currently recommended CRC screening
ools is given in Table 1 [6]. However, no reliable data are avail-
ble at present about the actual cost of various screening
ethods in relation to the gain of quality-adjusted life years
QALYs), as those will very much depend on the management
osts for the neoplastic lesions identified [7].
Differences in screening recommendations are motivated
o some extent by organizational and economic reasons but
lso by the scarcely documented public presumption that the
ore invasive endoscopic procedure might create negative
erceptions and impair the health-related quality of life
HRQoL) of potential screenees. Frequently, the medical com-
unity shares this worry and tends to favor less burdensome
but also less sensitive) imaging procedures for CRC screening
uch as CT-colonography. Non–evidence-based opinions can
urvive for long periods, not only in general but also in profes-
ional communities, and can potentially inhibit beneficial
edical developments.
At present, there is no generally acceptedmethod either to
ssess the perception and satisfaction of those screened or the
utcome of the screening procedures in CRC in terms of qual-
ty of life. The aim of the paper is to highlight the need for an
nstrument that assesses patient satisfaction with various
creening tools and the HRQoL resulting from differently de-
igned screening procedures. Thus, an overview is given of
ethods presently used to assess HRQoL in general. Thereaf-
er, a review is provided of the limited number of attempts to
ssess and describe participants’ perceptions of screening and
Table 1 – Characteristics of primary colorectal cancer (CRC)
Characteristics Fecal occult blood test (FOBT)
Invasiveness/discomfort Noninvasive, minimal
discomfort
Mode
dis
Risk of complications No risk of complications Com
Sensitivity Low sensitivity for target lesions
(25%–50%)
Fails to detect most polyps and
some cancers
False-positive results are
possible
Lowe
(70
Only
col
Need for additional
procedures and/or
repetition
Requires CS if positive
Useless/hazardous without
annual or biannual repetition§
Requ
Biops
pre
du
Repe
Reduction of CRC mortality Annual/biannual FOBT in ages
50–80 years can reduce CRC
mortality by 15%–33%
Effec
mo
in
* Indirect evidence available.
, low; , medium; §, high; RCT, randomized controlled trials.heir HRQoL before and after various CRC screening invita- tions and procedures. Some characteristics necessary for a
pecific HRQoL instrument to be used in CRC screening are
lso mentioned.
eneral Instruments for the Assessment of
ealth-Related Quality of Life
ackground and history
uality of life (QoL) is a notion that has been discussed, in
arious guises, throughout the history of philosophy. The no-
ion of QoL appears in the health care sector quite early, and in
he 1960s, the health-related literature started showing inter-
st for this concept [8,9].
According to Apolone [10], we can distinguish three out-
ome categories in healthmanagement: clinical/epidemiolog-
cal, humanistic, and economic (Table 2). The components of
he first type of outcome are measured by objective indicators
erived by diagnostic procedures and clinical events, such as
ecurrences and mortality. The economic outcome assess-
ent measures both direct and indirect costs, such as hospi-
alization, examinations, resource consumption, lost working
ours, and productivity reduction. The category of humanistic
utcomes contains the measures that will mainly be ad-
ressed in this review: severity of symptoms, functional im-
act of disease, well-being and QoL. These elements synthe-
ize the main part of the variety that reflects different
pproaches of health-related quality of life (HRQoL).
According to Spilker et al., HRQoL represents the functional
ffects of disease and therapeutic actions on the patient, in
he way the patient defines them [11], and is therefore consid-
red to be one of the primary indicators of outcome [12]. The
orld Health Organization (WHO) defines QoL as the subjec-
ening tools currently in use [6].
igmoidoscopy Colonoscopy (CS)
invasiveness and
ort
Invasive
Sedation useful/necessary§
ions are rare Complications are possible (bleeding/
perforations)§
sitivity than CS
%)
m and left part of the
e examined
High sensitivity (95%–100%)
Allows exploration of rectum and
entire colon§
S if positive
an be performed and
erous polyps removed
he test
every 5 years
Additional procedures not required
Biopsies can be performed and
precancerous polyps removed during
the test
Repetition every 10 years
ess in reducing CRC
y has not yet been proved
*
Effectiveness in reducing CRC mortality
has not yet been proved in RCT§*scre
S
rate
comf
plicat
r sen
%–80
rectu
on ar
ires C
ies c
canc
ring t
tition
tiven
rtalit
RCTive perception that an individual has of his position in life, in
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154 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 5 2 – 1 5 9cultural setting and in a set of values in which he lives, in
elation to his aims, expectations, and worries [13].
Many authors have provided a definition of HRQoL that takes
nto account only one particular component, such as functional
bilities [14], general satisfaction [15], well-being, and needs.
uch definitions have been translated into measures through
tandardized or semistandardized questionnaires [10].
In 1996, the American Society of Clinical Oncology (ASCO)
eclared the HRQoL as one of the most important elements to
e measured in patients with cancer [16]. Clinical studies of-
en undervalue the severity of patients’ symptoms, but in re-
ent years, more trials have incorporated HRQoL as a key end
oint [17,18]. In general, most questionnaires that measure
he HRQoL focus on physical, social, and emotional function-
Table 2 – Examples of outcome measures [10].
Outcome Events
Clinical/epidemiological Clinical events
Physical, laboratory m
Mortality
Humanistic Symptoms
Functional status
Health status
Well-being
QALY
Economic Direct medical aspect
Indirect medical aspe
ADL, activities of daily living; NHP, Nottingham Health Profile; SF-36,
Table 3 – Approaches to measuring quality of life (QoL).
Approach Source
1. Symptoms perception Medicine: patients express
perspectives on the bas
approach
2. Limitations in physical functions
and disability
Medicine: the QoL reflects t
consequences of sympt
physical functions
3. Limitations in many life aspects
(physical, psychological, social)
QoL corresponds to the W
definition (physical, psy
and social wellness)
4. Limitations for the realization of
personal expectations
Individuals: QoL is the achi
personal aims or the rea
personal life plans
5. Perception of failure in satisfying
personal needs
Individuals/researchers: QoL
according to the level of
of universal needs
6. Wellness measures
(psychological wellness and
satisfaction)
Individuals/researchers: QoL
satisfaction and happin
7. Utility Comparative evaluation a
status (perfect health or deatng [17], sometimes including the pain dimension and the so-
ial role limitation. The selection of an appropriate instru-
ent often depends on the special aim and design of the
linical and/or research project.
pproaches and instruments to measure HRQoL
nstruments of HRQoL can focus on one or numerous areas,
dopting different approaches (Table 3).
A first approach considers the symptoms perception. A
ymptom can be defined as the perception of an abnormal
ituation from a physical point of view (pain, urgency, dis-
omfort), an emotional point of view (associated with a
ental or psychological status, and with concern, worry,
Examples
res
Infections, myocardial stroke
Hypertension, tumor markers
Specific deaths (tumors), all causes
Symptoms checklist, pain scales
Karnofsky index [26], ADL [28]
SF-36 [33], SIP [31], NHP [32]
Psychological general well-being
Utility measures in terms of quality of life
Hospitalization, resource consumption
Productivity lost, work hours lost
t form 36-item questionnaire; SIP, Sickness Impact Profile.
Measures
personal
linical
Symptoms checklist (SCL-90-R®) [20]
Gastrointestinal Symptom Rating Scale (GSRS) [21]
The Kupperman Index [22]
Asthma Quality of Life Questionnaire (AQLQ) [23]
McGill Pain Questionnaire [24]
n
Physical Function Scales:
Barthel Index [25]
Karnofsky Performance Index [26], ECOG score [27]
Activities of daily living (ADL) [28]
Townsend Scale [29]
health
gical,
Health status measures, HRQoL (physical,
psychological, social):
Sickness Impact Profile (SIP) [31]
Nottingham Health Profile (NHP) [32]
SF-36 [33]
SF-12 [34]
ent of
ion of
Individual approach:
Repertory Grid Technique (RGT) [35]
Schedule for the Evaluation of Individual Quality of
Life (SEIQOL) [36]
fined
faction
Needs-based approach
Beck Depression Inventory [37]
Affect-Balance Scale [38]
Delighted-Terrible Scale [39]
Psychological General Well-Being Index (PGWI) [40]
health Standard gamble, time trade-off:easu
s
ctstheir
is of c
he
oms o
HO’s
cholo
evem
lizat
is de
satis
as
ess
mong
h) Health Utility Index (HUI) [41])
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155V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 5 2 – 1 5 9rustration), and a cognitive aspect (memory, concentra-
ion) [19]. Symptoms appear in questionnaires to measure
RQoL in three ways:
as frequency and intensity scales (symptoms checklist);
as symptoms scales linked with questions about the
degree of bother;
as direct components of HRQoL.
he questionnaires using this type of approach include the
ymptoms checklist [20], the Gastrointestinal Symptom Rat-
ng Scale (GSRS) [21], the Kupperman Index [22], and the
sthma Quality of Life Questionnaire (AQLQ) [23]. The most
sed questionnaire to measure pain is the McGill Pain Ques-
ionnaire [24].
A second approach values the HRQoL according to the phys-
cal functions and the related functional disability. The most
ommon scale to measure disability is the Barthel Index [25].
nother is the frequently used Karnofsky Performance Index
26], with the ECOG score (also called theWHO or Zubrod score)
or quantifying cancer patients’ general well-being [27]. Exam-
les of instruments to assess daily activities include the activi-
ies of daily living (ADL) scale [28] and the Townsend scale [29].
A third approach, developed in the late 1970s, is the survey of
lobal satisfaction with HRQoL, which is based on the assump-
ion that the sum of physical, psychological, and social compo-
ents is of greatest importance [30]. The instruments developed
n this period are defined as generalmeasures of HRQoL, as they
an be applied in any type of disorder. The Sickness Impact Pro-
le (SIP) [31], the NottinghamHealth Profile (NHP) [32], the Short
orm 36-ItemHealth Survey (SF-36) [33], and its shortened form,
he SF-12 [34], are the most diffused examples.
Other approaches to measure the HRQoL take into account
he patient’s limits in the realization of personal expectations,
or example, the Repertory Grid Technique (RGT) [35] and the
chedule for the Evaluation of Individual Quality of Life
SEIQOL) [36]. The wellness approach, developed in the 1990s,
akes into account psychological wellness and personal satis-
action. The Beck Depression Inventory [37], the Affect-Bal-
nce Scale [38], the Delighted-Terrible Scale [39], and the Psy-
hological General Well-Being Index [40] are all used
requently for psychological disturbances.
One last approach ismainly based on utility. It captures the
mplications of a new concept of health, in terms of value of
ife. This approach is based on the assumption that individu-
ls make rational choices and express preferences comparing
heir health statuswith a hypothetical health status. One such
nstrument is the Health Utility Index (HUI) [41], which is used
ainly in economic cost-utility analysis.
Also the EuroQol [13] represents the attempt to develop a
eneral, standardized instrument to describe and evaluate the
RQoL independently from the specific disease. Another in-
trument of this type is the WHO Quality of Life (WHOQOL)
42]. The Quality of Life Inventory (QoLI) [43] evaluates the
RQoL assuming that general satisfaction is a result of the
um of the satisfaction in specific areas of life that the indi-
idual believes to be important.
From this description of the main instruments to measurehe HRQoL some reflections can be derived. Any attempt to sntegrate more dimensions automatically increases the num-
er of items, thereby potentially limiting the effectiveness of
he instruments. The multiplicity of instruments described
bove also highlights that there is no common agreement on
hat is “quality of life.”
At present, it might be advisable to use general instru-
ents, like the SF-36, for a comparison with other health care
ituations or disorders, and to add validated disease-specific
nstruments, if they exist. However, in previously noncovered
elds of health care, innovative approaches are needed, in-
luding the design of new purpose-tailored approaches.
creenee Perception and Health-Related Quality
f Life in Colorectal Cancer Screening
ackground and past experiences
RC ideallymeets the criteria for screening because of its high
revalence, its long asymptomatic phase, and the existence of
reatable precancerous lesions [44]. Several screening meth-
ds have been evaluated, such as FOBT [45,46], sigmoidoscopy
47,48], colonoscopy [49], and, recently, CT-colonography [50].
olonoscopy has become the preferred test for physicians—
nd particularly gastroenterologists—because of its possibil-
ty to visualize the entire large bowel, to take histological spec-
mens from lesions suspicious of cancer, and to directly
emove clinically significant precancerous lesions—adeno-
as—with the aim of reducing the future incidence of CRC
51]. Nevertheless, colonoscopy is less accepted as a primary
creeningmethod for CRC than the various types of FOBTs and
he less invasive sigmoidoscopy [52].
The barriers hindering the widespread diffusion of
olonoscopy-based primary screening campaigns include
orries of the potential screenee (e.g., pain, other discom-
ort, potential complications connected with the procedure)
nd the cumbersome and poorly tolerated cleansing prepa-
ation necessary for an optimal result of the screening pro-
edure.
Despite the evident benefits of CRC prevention, screenees’
otential negative perceptions and impaired HRQoL still have
o be considered. Moreover, it is important to recall that the
ifetime risk of CRC is about 6% and, therefore, even if colonos-
opy were completely effective in eliminating CRC, 94% of the
creened patients would not benefit from screening [44]. Little
s known about the psychological impact on healthy individ-
als of receiving an invitation for a screening test, about the
orry associated with the screening procedure itself, the re-
eiving of positive (pathological) results, and the presumed
enefit of a negative result. What follows here is a review of
he data published so far. Currently, most tests used to mea-
ure HRQoL are generic and not designed for a specific disor-
er or health condition (Table 4).
In the general population theworry about CRC is lowor nonex-
stent [53,54], in contrast topersonswith a familyhistory of cancer.
mong the latter, the perception of cancer risk is increased and
eems to improve the adherence to screening [55]. Thus, there are
wo possibilities regarding cancerworry: itmay facilitate or inhibit
creening participation. Both theories have received support by
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156 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 5 2 – 1 5 9revious studies regarding breast cancer screening [56,57] and also
RC screening [54,58]. At present, there is no definitive knowledge
nwhether or not screening announcement/invitation can reduce
ancer worry and, thereby, what the impact on the HRQoL of the
opulationmight be.
HRQoL studies have referred to screening campaigns for
rostate, breast, or cervical cancer and shown limited negative
ffects on general anxiety (even in case of false-positive results)
hat tend to diminish with a long-standing follow-up [59–64].
The National Cancer Institute’s prostate, lung, colorectal,
nd ovarian (PLCO) cancer screening trial is a long-lasting
roject focused on the effects of screening for these cancers
65]. As part of the trial, an ancillary study was conducted to
ssess the impact on HRQoL of receiving normal or abnormal
creening results [66]. The SF-12 questionnaire was used to
ssess the HRQoL, and four items from the seven-item Intru-
ion Subscale of the Impact of Event Scale (IES) were added to
ssess cancer specific distress and to evaluate the partici-
ants’ responses to the screening test. Subjects with a new
ancer diagnosis were excluded from the analysis. A total of
76 subjects were enrolled in the study. The data reported a
etter QoL in participants than in the general population, ir-
espective of the screening results (normal or abnormal; ab-
ormal results were mainly due to an abnormal sigmoidos-
opy). Older patients and those with a first-degree relative
ith cancer reported a better HRQoL score than younger per-
ons and those without family history of cancer. Normal re-
ults influenced the trial adherence positively, as subjects
ithout pathological findings were encouraged to continue
heir participation.
In another study, theHRQoL of 225 subjects participating in
colonoscopy-screening campaign was measured using the
F-36 questionnaire [67]. The participants completed the
uestionnaire before and after undergoing colonoscopy. Sig-
ificantly more participants had better vitality scores and
ental health scores after colonoscopy. On the contrary, no
mprovement in the physical health domains of the SF-36 was
een, irrespective of the colonoscopy results.
A study in Gothenburg, Sweden, assessed the worries as-
ociated with CRC screening using a specifically designed
uestionnaire to get ameasure of the amount of worry follow-
ng an invitation to amass FOBT-screening program [68]. After
creening, a telephone or personal interview was conducted
o assess the worry in the case group (individuals attending
he screening). The control group consisted of persons who
Table 4 – Questionnaires used to assess quality of life in su
Authors Questionn
Lindholm et al. [68] Self-constructed questionnaire and tel
Taylor et al. [66] SF-12, Impact of Event Scale, satisfacti
Miles and Wardle [72] Health Anxiety Questionnaire, State-T
Consequence of Screening Question
Taupin et al. [67] SF-36
Orbell et al. [76] Illness Perception Questionnaire, Ways
State-Trait Anxiety Inventory
SF-12, short form 12-item questionnaire.
*The questionnaire was modified in part for the specific aim of the sad received the invitation letter but had not attended the tcreening program. A total of 3548 persons were analyzed:
4%of participants reported that theywere “notworried at all”
fter receiving the invitation letter. However, severe worry
as expressed by 13% of themen and 19% of thewomen in the
articipants’ group, with similar data in the nonparticipants’
roup (10% and 19%, respectively). Moreover, about 65% of the
articipants and 78% of the nonparticipants reported that
heir daily life was affected to various extents after the start of
he screening campaign. Lower education level was associ-
ted with higher level of worry. Worry disappeared in thema-
ority of the patients after endoscopy and 98% of the subjects
ppreciated the possibility to participate in the screening
ampaign. The results showed that, despite the increased
orry, most of participants did not experience an increase in
nxiety. In addition, the endoscopic procedure had a positive
ffect on reducing worry.
Another Scandinavian work addressed the psychological
ffect of attending a colonoscopy screening program [69]. In
his study, subjects participating in the Telemark (Norway)
creening program for detection and removal of polyps re-
eived two questionnaires by mail: the Goldberg’s General
ealth questionnaire and the Hospital Anxiety and Depres-
ion Scale [70,71]. Subjects completed the questionnaire 15
ays, 3 months and 17 months after colonoscopy. A control
roup of subjects not attending the screening program also
ompleted the questionnaires. The score for both the ques-
ionnaires was lower in the group of subjects attending the
creening, indicating a lowered level of psychiatric distress.
Miles andWardle analyzed the psychological distress aris-
ng from attending flexible sigmoidoscopy screening in the
nited Kingdom [72]. A shortened form of the Health Anxiety
uestionnaire (HAQ) [73], the State-Trait Anxiety Inventory
STAI) [74], and the Psychological Consequences of Screening
uestionnaire (PCQ) [75] were used. Moreover, additional
uestions were designed specifically to evaluate the attitude
o accept medical reassurance, to seek medical information,
o investigate the presence of bowel symptoms, and to count
he number of general practitioner visits prior to screening.
n total, 3535 subjects completed the questionnaires before
nd after the screening. The study showed that cancer worry
ecreased significantly after screening and that a higher level
f prescreening health anxiety was associated with greater
eduction in bowel cancer worry. There was no relationship
etween screening outcome and change in anxiety level. Also,
n this study participants expressed a positive judgment on
ts participating in screening program.
sed Type of questionnaire
ne interview Not validated
th Decision scale Validated*
nxiety Inventory, psychological
, and ad hoc questions
Validated and not validated
Validated
oping Questionnaire, Validated*bjec
aire u
epho
on wi
rait A
naire
of Che experience of screening.
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157V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 5 2 – 1 5 9In a recent paper the emotional reactions to a positive
OBT result were evaluated as a part of a CRC screening
ilot program in the United Kingdom [76]. Subjects were
ligible for the study after they had completed all the
creening steps (FOBT and colonoscopy). Three adapted
uestionnaires were used: the IPQ-R (Revised Illness Per-
eption Questionnaire) was used to define cognitive and
motional representation of illness [77]; the WCQ (Ways of
oping Questionnaire) was used to analyze the strategies to
anage the positive FOBT result [78]; and the State-Trait
nxiety Inventory was used to assess the anxiety level [74].
he data were analyzed according to the presence of cancer,
denoma, or negative screening outcome. Cancer patients
eported their diagnosis as more distressing than patients
ith polyps or negative results, but they held stronger be-
iefs in the efficacy of treatment than the other two groups.
oreover, the patients in the cancer group were less likely to
ttribute their disease to personal lifestyle factors. State anxiety
id not differ with screening outcome between the groups, sug-
esting that anxiety may be an individual characteristic. This
tudy concluded that the presence of colonic neoplasm was in
eneral not associated with escape-avoidance strategies but re-
ulted in positive self-change behavior.
Globally, the data show that screening for CRC has a pos-
tive psychological effect even in subjects with a positive
i.e., pathological) result. However, no conclusive answer
xists for possible negative consequences of screening ac-
ivities for specific cancer forms. Even if the initial data
oming from the big screening trials using FOBT have
hown a reduction in CRC mortality [45,46,79], an increased
ortality from cardiac disease has been suggested in the
ollow-up of individuals that underwent screening colonos-
opy [80]. This data might point to adverse psychological
ffects. Hoff et al. (2001) reported the long-term results of a
igmoidoscopy screening program, showing that, after the
nitial screening procedure, the incidence of CRC was lower
n the group that underwent the screening than in the non-
creened control group [81]. However, the overall survival
ate in the screening group was similar to that in the control
roup because of an excess mortality for nonmalignant disor-
ers (mainly coronary heart disease). Moreover, they found a
rend toward a higher increase in body mass index (BMI) for
atients without polyps and a reduction of smoking for sub-
ects with polyps. The same authors analyzed the changes in
ifestyle variables (BMI, smoking habits, physical activity, and
egetable consumption) in the screened group and in the con-
rol group; they found an undesirable lifestyle change associ-
ted with CRC screening [82]. These observations suggest that
he positive psychological effect of screening could inversely
ffect the attention to negative lifestyle factors. However, the
oncerns about such a “complacency effect” in persons who
eceived a favorable screening outcome, leading to deteriora-
ion in general health behavior, were contradicted by the data
f Miles et al. [83]. In their study, the authors evaluated health
ttitudes and practices (such as eating fruit, avoiding fatty
ood, taking regular exercise, smoking status, and participa-
ion in cervical and breast screening) in a group of subjects
ttending the UK sigmoidoscopy trial. The results showed a
ositive change for the majority of the health attitudes and sractices and no differences in the health behaviors between
ubjects with a negative screening test result compared to
hose with pathological findings.
Thus, participants’ perception andHRQoL inCRC screening
ave rarely been addressed in the past and often used a com-
ination of general HRQoL questionnaires and nonvalidated
lements (Table 4). Nonspecific and validated question-
aires—comparable to the Inflammatory BowelDiseaseQues-
ionnaire (IBDQ) [84]—are presently not available to assess
RQoL during CRC screening.
A specific instrument with the purpose to assess the per-
eption and the HRQoL of CRC screening participants is still
acking. Such an instrument could primarily serve clinical and
ublic health studies at a national and international level in
rder for screening providers to audit the quality of their own
ctivities and to compare themwith those obtained by others.
he instrument should cover all phases of the screening pro-
ess from invitation onward, including the period when
creening results are reported to the screenees, as well as a
ertain period of follow-up, independent of a positive (lesion
ound and treated) or negative outcome. Psychological antici-
ations and reactions of the participants should be addressed
s much as the technical quality of the screening method and
rganizational details of the screening.
The findings reported here provide insights into the impact
f CRC screening in HRQoL and give arguments in favor of
creening programs. The HRQoL seems to be positively influ-
nced by attending screening independently by its outcome.
his is a crucial point as most subjects undergoing screening
est will not have the disease andwill not benefit directly from
he test. The observed beneficial effect on HRQoL could be a
ersuasive argument to increase the attendance rate to
creening for CRC.
ummary and Conclusions
n this overview, after a review of the general instruments for
he assessment of HRQoL and the outcome of somemore spe-
ific surveys associated with CRC screening, we have pointed
ut the elements that should be part of a questionnaire-in-
trument to be used in various forms of CRC screening.
HRQoL has become ubiquitously implemented over the
ast 30 years in the outcome assessment of health care pro-
esses, diagnostics, treatment, and organization. Initially,
RQoL was seen as an important outcome in disorders in
hich therapeutic interventions could be very demanding
nd evenmore detrimental to patients than the disorder itself
like the chemotherapy of malignancies) and therefore limit-
ng the applicability of such measures. More recently, HRQoL
as been useful in more benign disorders and has been ac-
epted as one of the parameters contributing to decisions of
ealth care providers, insurers, and national and interna-
ional drug agencies (e.g., the FDA and EMA) to license certain
nterventions.
Prevention is widely accepted as an important part of the
anagement of benign and malignant diseases; therefore,
t is reasonable that screening processes and procedures
hould undergo objective audits of their quality. As a con-
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ssessed. Until now, this type of assessment in CRC screen-
ng has been used only sporadically, mainly applying tradi-
ional generic instruments or nonvalidated questionnaire
onstructs. An internationally accepted instrument does
ot yet exist and should therefore be created. Because the
erceived HRQoL is an important self-reported outcome in
he community, it is conceivable that positive reports can be
n incentive for the potential screening population to ad-
ere to calls for screening.
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